Improved Measures of Quality of Life, Lipid Profile and Lipoatrophy after Treatment Interruption in HIV-Infected Patients with Immune Preservation: results of ACTG 5170

Por Skiest, Daniel J., Krambrink, Amy, Su, Zhaohui, Robertson, Kevin R., Margolis, David M.
Publicado em 2008

CD4(+) T-Cell Decline after the Interruption of Antiretroviral Therapy in ACTG A5170 Is Predicted by Differential Expression of Genes in the Ras Signaling Pathway

Por Vahey, Maryanne T., Wang, Zhining, Su, Zhaohui, Nau, Martin E., Krambrink, Amy, Skiest, Daniel J., Margolis, David M.
Publicado em 2008

Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

Por Schouten, Jeffrey T., Krambrink, Amy, Ribaudo, Heather J., Kmack, Anne, Webb, Nancy, Shikuma, Cecilia, Kuritzkes, Daniel R., Gulick, Roy M.
Publicado em 2010

Response to Vicriviroc in Treatment-Experienced Subjects Using an Enhanced Sensitivity Co-receptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211

Por Su, Zhaohui, Gulick, Roy M., Krambrink, Amy, Coakley, Eoin, Hughes, Michael D., Han, Dong, Flexner, Charles, Wilkin, Timothy J., Skolnik, Paul R., Greaves, Wayne L., Kuritzkes, Daniel R., Reeves, Jacqueline D.
Publicado em 2009

Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection

Por Janes, Holly, Friedrich, David P., Krambrink, Amy, Smith, Rebecca J., Kallas, Esper G., Horton, Helen, Casimiro, Danilo R., Carrington, Mary, Geraghty, Daniel E., Gilbert, Peter B., McElrath, M. Juliana, Frahm, Nicole
Publicado em 2013

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected, Treatment-Experienced Patients

Por Wilkin, Timothy J., Su, Zhaohui, Krambrink, Amy, Long, Jianmin, Greaves, Wayne, Gross, Robert, Hughes, Michael D., Flexner, Charles, Skolnik, Paul R., Coakley, Eoin, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R., Gulick, Roy M.
Publicado em 2010

Detection of Nonnucleoside Reverse-Transcriptase Inhibitor–Resistant HIV-1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy

Por Hare, C. Bradley, Mellors, John, Krambrink, Amy, Su, Zhaohui, Skiest, Daniel, Margolis, David M., Patel, Sheran S., Barnas, Douglas, Frenkel, Lisa, Coombs, Robert W., Aweeka, Francesca, Morse, Gene D., Haas, David W., Boltz, Valerie, Palmer, Sarah, Coffin, John, Havlir, Diane V.
Publicado em 2008

Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

Por Tsibris, Athe M. N., Paredes, Roger, Chadburn, Amy, Su, Zhaohui, Henrich, Timothy J., Krambrink, Amy, Hughes, Michael D., Aberg, Judith A., Currier, Judith S., Tashima, Karen, Godfrey, Catherine, Greaves, Wayne, Flexner, Charles, Skolnik, Paul R., Wilkin, Timothy J., Gulick, Roy M., Kuritzkes, Daniel R.
Publicado em 2009